BURROUGHS WELLCOME SEEKS INJUNCTION AGAINST SMITHKLINE FAMVIR SALES
This article was originally published in The Tan Sheet
Executive Summary
BURROUGHS WELLCOME SEEKS INJUNCTION AGAINST SMITHKLINE FAMVIR SALES, claiming that the new herpes zoster drug infringes two patents held by the company covering its antiviral drug, Zovirax (acyclovir). In an Aug. 23 complaint fried in Raleigh, N.C. federal court, Burroughs Wellcome urged the court to find that SmithKline Beecham's manufacture, use or sale of Famvir (famciclovir) infringes its patents. Wellcome is seeking a permanent injunction against the drug's use and treble damages with interest. The company is requesting a jury trial.